Category: News

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two clinical studies presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference this week: data from the Global Paradise System (GPS) Registry demonstrated a 19.6 mmHg reduction in office systolic blood pressure at six months with the Paradise™ Ultrasound Renal Denervation (uRDN) system; and the pooled analysis of data from the RADIANCE global clinical trial program showed a sustained reduction of 15.7 mmHg in office systolic blood pressure at 24 months. The Paradise uRDN system is a device-based adjunctive therapy for patients with uncontrolled and resistant hypertension whose blood pressure cannot be properly managed with lifestyle changes and medication.

Palo Alto, CA, USA – May 15, 2026 – In recognition of World Hypertension Day 2026, taking place on Sunday, May 17, Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its detection, management, and treatment. Affecting more than one billion people worldwide, hypertension remains a leading risk factor for serious cardiovascular conditions, making continued innovation and patient engagement essential. This year’s global theme, “Controlling Hypertension Together” emphasizes the importance of early detection and sustained management to support longer, healthier lives.

Palo Alto, CA, USA – May 15, 2026 – In recognition of World Hypertension Day 2026, taking place on Sunday, May 17, Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its detection, management, and treatment. Affecting more than one billion people worldwide, hypertension remains a leading risk factor for serious cardiovascular conditions, making continued innovation and patient engagement essential. This year’s global theme, “Controlling Hypertension Together” emphasizes the importance of early detection and sustained management to support longer, healthier lives.

Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has been recognized with a TAG award in the Medical Devices: Cardiovascular Therapeutic Innovation category.

Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and will conduct co-promotion with Otsuka Pharmaceutical.

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two clinical studies presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference this week: data from the Global Paradise System (GPS) Registry demonstrated a 19.6 mmHg reduction in office systolic blood pressure at six months with the Paradise™ Ultrasound Renal Denervation (uRDN) system; and the pooled analysis of data from the RADIANCE global clinical trial program showed a sustained reduction of 15.7 mmHg in office systolic blood pressure at 24 months. The Paradise uRDN system is a device-based adjunctive therapy for patients with uncontrolled and resistant hypertension whose blood pressure cannot be properly managed with lifestyle changes and medication.

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced that the Centers for Medicare and Medicaid Services (CMS) has issued its National Coverage Determination (NCD) for Renal Denervation (RDN), including Recor’s Paradise® Ultrasound Renal Denervation (uRDN) system, a device-based therapy for patients with uncontrolled hypertension whose blood pressure cannot be properly managed with lifestyle changes and medication.

Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal Denervation (uRDN) system has received approval for manufacturing and marketing in Japan for the treatment of resistant hypertension. This marks the first approval in the country for a medical device indicated for the disease.

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), appreciate the American Heart Association (AHA) and American College of Cardiology (ACC) for highlighting renal denervation (RDN) as a therapeutic option for resistant or uncontrolled hypertension in the joint 2025 Guidelines. The AHA/ACC Guidelines integrate the latest scientific data, regulatory advances, and treatment paradigms into a recommendation for clinicians in the cardiology field, and the 2025 edition emphasizes the growing confidence in RDN as a beneficial treatment option for patients with resistant or uncontrolled hypertension.